| 000 | 04342naa a22006497i 4500 | ||
|---|---|---|---|
| 001 | UMUN-OA-20261005-MLS-032 | ||
| 003 | local | ||
| 005 | 20261005174904.0 | ||
| 006 | m o d | ||
| 007 | cr|||||||||||| | ||
| 008 | 261005s2023 xx o u000 0 eng d | ||
| 024 | 7 |
_a10.1186/s12967-023-04292-3 _2doi |
|
| 035 | _a(local)EuropePMC:PMC10327392 | ||
| 040 |
_alocal _beng _clocal |
||
| 041 | 0 | _aeng | |
| 100 | 0 |
_aGunjan Dagar _eauthor. |
|
| 245 | 1 | 0 |
_aHarnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. / _cGunjan Dagar; Ashna Gupta; Tariq Masoodi [and others]. |
| 264 | 1 |
_a[Place of publication not identified] : _bBMC, _c2023. |
|
| 300 | _a1 online resource (1 article). | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 500 | _aThe source lists 17 contributors; the first 12 names are recorded as access points. The complete source author list is retained in the catalogue manifest. | ||
| 500 | _aPublication type: Review article. | ||
| 500 | _aLinked open-access copy: published version. | ||
| 506 | 0 |
_aOpen access; no subscription required for the linked open-access version. _fUnrestricted online access _2star |
|
| 520 | 3 | _aTraditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and modified to target tumor-associated antigens. CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma by targeting CD-19 and B-cell maturation antigens. Bi-specific chimeric antigen receptors may contribute to mitigating tumor antigen escape, but their efficacy could be limited in cases where certain tumor cells do not express the targeted antigens. Despite success in blood cancers, CAR-T technology faces challenges in solid tumors, including lack of reliable tumor-associated antigens, hypoxic cores, immunosuppressive tumor environments, enhanced reactive oxygen species, and decreased T-cell infiltration. To overcome these challenges, current research aims to identify reliable tumor-associated antigens and develop cost-effective, tumor microenvironment-specific CAR-T cells. This review covers the evolution of CAR-T therapy against various tumors, including hematological and solid tumors, highlights challenges faced by CAR-T cell therapy, and suggests strategies to overcome these obstacles, such as utilizing single-cell RNA sequencing and artificial intelligence to optimize clinical-grade CAR-T cells. | |
| 540 |
_aCreative Commons Attribution. See the linked licence for the applicable terms. _uhttps://creativecommons.org/licenses/by/4.0/ |
||
| 546 | _aIn English. | ||
| 588 | 0 | _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. | |
| 590 | _aCourse allocation: B. Sc. Medical Laboratory Science. | ||
| 650 | 4 | _aTumor antigens | |
| 650 | 4 | _aImmunotherapy | |
| 650 | 4 | _aHematological malignancy | |
| 650 | 4 | _aSolid tumor | |
| 650 | 4 | _aCytokine Release Syndrome | |
| 650 | 4 | _aAntigen Escape | |
| 653 | _aB. Sc. Medical Laboratory Science | ||
| 653 | _aUMUN open access collection | ||
| 653 | _ahematology | ||
| 655 | 4 | _aReview articles. | |
| 700 | 0 |
_aAshna Gupta _eauthor. |
|
| 700 | 0 |
_aTariq Masoodi _eauthor. |
|
| 700 | 0 |
_aSabah Nisar _eauthor. |
|
| 700 | 0 |
_aMaysaloun Merhi _eauthor. |
|
| 700 | 0 |
_aSheema Hashem _eauthor. |
|
| 700 | 0 |
_aRavi Chauhan _eauthor. |
|
| 700 | 0 |
_aManisha Dagar _eauthor. |
|
| 700 | 0 |
_aSameer Mirza _eauthor. |
|
| 700 | 0 |
_aPuneet Bagga _eauthor. |
|
| 700 | 0 |
_aRakesh Kumar _eauthor. |
|
| 700 | 0 |
_aAmmira S Al-Shabeeb Akil _eauthor. |
|
| 773 | 0 |
_tJournal of translational medicine _gVol. 21, no. 1, (2023), pages/article 449 _x1479-5876 |
|
| 856 | 4 | 0 |
_uhttps://europepmc.org/articles/PMC10327392 _yRead open-access publication _zOpen access. _70 |
| 884 |
_aCourse selection and automated MARC21 enrichment from Europe PMC metadata. _g20261005 _khttps://europepmc.org/articles/PMC10327392 _qlocal |
||
| 942 | _n0 | ||
| 999 |
_c1174 _d1174 |
||